Author Interviews, Brigham & Women's - Harvard, Cancer Research, COVID -19 Coronavirus, Prostate, Prostate Cancer, Surgical Research, Urology / 01.02.2021

MedicalResearch.com Interview with: [caption id="attachment_56523" align="alignleft" width="200"]David-Dan Nguyen Research Fellow | Center for Surgery and Public Health, Brigham and Women's Hospital MPH (Health Policy) Student | Harvard T.H. Chan School of Public Health Medical Student | McGill University Mr. Nguyen[/caption] David-Dan Nguyen Research Fellow | Center for Surgery and Public Health, Brigham and Women's Hospital MPH (Health Policy) Student | Harvard T.H. Chan School of Public Health Medical Student | McGill University MedicalResearch.com: What is the background for this study? Response: The COVID-19 pandemic has forced hospitals to delay the definitive treatment of cancers via surgery or radiation therapy. While previous evidence has shown that delaying the treatment of low-risk prostate cancer is not associated with worse outcomes, treatment delays for intermediate-risk and high-risk prostate cancer are more controversial. As such, we sought to determine if delays for these disease states negatively impacted oncological outcomes.
Author Interviews, COVID -19 Coronavirus, JAMA, Race/Ethnic Diversity, Social Issues / 29.01.2021

MedicalResearch.com Interview with: [caption id="attachment_56495" align="alignleft" width="133"]Renuka Tipirneni, MD, MSc, FACP Assistant Professor Holder of the Grace H. Elta MD Department of Internal Medicine Early Career Endowment Award 2019-2024 University of Michigan Department of Internal Medicine, Divisions of General Medicine and Hospital Medicine, and Institute for Healthcare Policy & Innovation Ann Arbor, MI Dr. Tipirneni[/caption] Renuka Tipirneni, MD, MSc, FACP Assistant Professor Holder of the Grace H. Elta MD Department of Internal Medicine Early Career Endowment Award 2019-2024 University of Michigan Department of Internal Medicine, Divisions of General Medicine and Hospital Medicine, and Institute for Healthcare Policy & Innovation Ann Arbor, MI MedicalResearch.com: What is the background for this study? Response: As there have been significant racial/ethnic disparities in US COVID-19 infections and health outcomes including death, we investigated county-level social factors that may explain these inequities. Specifically, we examined the association between the Centers for Disease Control and Prevention’s Social Vulnerability Index (a composite measure of social disadvantage) and COVID-19 incidence and mortality rates. We found that with just a one-point increase in the ten-point scale, there was a 14% increase in incidence rate and 14% increase in mortality rate. This equated to approximately 87 excess COVID-19 infections and 3 deaths per 100,000 population. 
Author Interviews, Biomarkers, COVID -19 Coronavirus / 25.01.2021

MedicalResearch.com Interview with: [caption id="attachment_56468" align="alignleft" width="167"]Marlene Cano MD. PhD. Post-Doctoral Research Fellow in Pulmonary Transplant Immunology Division of Pulmonary and Critical Care Department of Medicine Washington University/Barnes-Jewish Hospital Saint Louis, MO Dr. Cano[/caption] Marlene Cano MD. PhD. Post-Doctoral Research Fellow in Pulmonary Transplant Immunology Division of Pulmonary and Critical Care Department of Medicine Washington University/Barnes-Jewish Hospital Saint Louis, MO MedicalResearch.com: What is the background for this study? How does this test differ from other tests for COVID-19?   Response: We know COVID-19 causes a wide spectrum of disease, and that while many develop only mild uncomplicated illness, others develop severe respiratory failure, multi-organ failure and death. These patients often require prolonged hospitalization, ICU level care and even mechanical intubation for respiratory support. However, we still do not have a great way to identify which patients are likely to develop severe disease. We felt it was important to have a test that could act as sort of a ‘biomarker’ that we could measure early in COVID-19 patients and would help predict which patients would develop severe disease. From prior work, we knew that mitochondrial DNA, which are proinflammatory molecules that are released into the circulation from damaged organs could be this such ‘biomarker’. So, we measured the levels of mitochondrial DNA circulating in the plasma of patients with COVID-19 at the time they first presented to the hospital. Then we investigated if higher levels of mitochondrial DNA indeed predict the development of more severe disease. Currently there are no ‘biomarker’ tests specific for COVID-19. We do currently measure levels of other markers in the hospital that we feel might help us assess overall how sick patients may be, but these are very non-specific and assess only level of inflammation. This test instead can measure level of tissue injury.
Author Interviews, Infections, OBGYNE, Pharmaceutical Companies / 21.01.2021

MedicalResearch.com interview with: Dr. Stephen Brand, Chief Development Officer Mycovia Pharmaceuticals [caption id="attachment_56443" align="alignleft" width="189"]Dr.Stephen-Brand.jpg Dr. Brand[/caption]  Dr. Stephen Brand discusses the results of Mycovia’s three Phase 3 studies for recurrent vaginal yeast infections (RVVC )and what’s next for the company.  MedicalResearch.com: What is the background for these Phase 3 studies? Answer: Our Phase 3 clinical program for our oral therapy oteseconazole was comprised of three trials enrolling more than 870 patients at 176 sites across 11 different countries. Two of these trials, referred to as VIOLET were identical Phase 3 randomized, double-blind, placebo-controlled clinical trials to evaluate the safety of oteseconazole and its ability to prevent episodes of recurrent vulvovaginal candidiasis (RVVC), commonly referred to as chronic yeast infection. The trials took place over 48 weeks in subjects with an established disease history of at least three episodes of acute VVC in the past 12 months. More than 650 patients randomized at 125 sites across 11 countries. The VIOLET trials consisted of two parts: During the first part of the study which lasted two weeks after patients presented with an active VVC episode, patients were treated with three sequential 150mg doses of fluconazole. The second part consisted of 12 weeks, when the patient either took oteseconazole 150mg or a placebo once weekly (according to a random assignment), and then a 36-week follow-up period. In addition, subjects participating in the VIOLET trials in the U.S. who remained infection-free at their Week 48 visit were offered the opportunity to participate in an extension study and are being monitored for an additional 48 weeks to further define the long-term protection profile of oteseconazole. Eighty-five subjects are enrolled. The third Phase 3 study, called ultraVIOLET, was designed to complement and extend VIOLET as a 50-week randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of oteseconazole. In addition the study compared the effectiveness of oteseconazole compared to fluconazole, the current standard of care, to treat an acute VVC infection in the RVVC population. A total of 220 patients were randomized at 51 sites in the U.S. for the ultraVIOLET trial. The ultraVIOLET trial consisted of two parts: In the first part of the study RVVC subjects presenting with an active infection were randomized to receive either 2 days of dosing with oteseconazole or 3 sequential 150 mg doses of fluconazole (every 72 hours). The second part consisted of 11 weeks, when the patient took either oteseconazole or a placebo weekly (according to the random assignment from the first part of the study), and then a 37-week follow-up period.
Author Interviews, COVID -19 Coronavirus / 20.01.2021

MedicalResearch.com Interview with: [caption id="attachment_56438" align="alignleft" width="155"]Dr Caroline Wei Shan Hoong, MBBS, MRCP Associate Consultant Endocrinologist Department of General Medicine Woodlands Health Campus National Healthcare Group, Singapore Dr. Wei Shan Hoong[/caption] Dr Caroline Wei Shan Hoong, MBBS, MRCP Associate Consultant Endocrinologist Department of General Medicine Woodlands Health Campus National Healthcare Group, Singapore MedicalResearch.com: What is the background for this study? Response: In the course of our clinical work, we have noticed a predominance of musculoskeletal complaints among some of COVID-19 patients who are otherwise clinically well, and a small subset of them who develop a viral arthralgia (joint pains) sometimes occurring separately from the onset of acute respiratory symptoms. Besides a few isolated case reports, there was not much described about COVID-19 associated viral arthralgia in the literature. Clinicians are well aware of the need to test for COVID-19 when patients present with cough or shortness of breath. However, when they present as joint pains without any respiratory symptoms, a diagnosis of COVID-19 could easily be missed. Due to overlapping clinical features like low platelet count and elevated liver enzymes, they could easily be misdiagnosed as having other vector-borne infections such as dengue fever, if clinicians do not have a high clinical suspicion of COVID-19. Hence we decided to describe the epidemiology and various presentations of musculoskeletal manifestations of COVID-19 in our cohort of patients. 
Author Interviews, COVID -19 Coronavirus, Diabetes, Race/Ethnic Diversity / 16.01.2021

MedicalResearch.com Interview with: [caption id="attachment_56430" align="alignleft" width="150"]Anath Shalev, M.D. Professor of Medicine Nancy R. and Eugene C. Gwaltney Family Endowed Chair in Juvenile Diabetes Research Director, Comprehensive Diabetes Center University of Alabama at Birmingham Birmingham, AL Dr. Shalev[/caption] Anath Shalev, M.D. Professor of Medicine Nancy R. and Eugene C. Gwaltney Family Endowed Chair in Juvenile Diabetes Research Director, Comprehensive Diabetes Center University of Alabama at Birmingham Birmingham, AL  MedicalResearch.com: What is the background for this study?  What is metformin normally prescribed for? Response: Diabetes has been recognized as one of the major comorbidities associated with higher mortality in the context of the spreading COVID-19 pandemic, but ways to improve outcome in this at-risk population are lacking. Metformin is the most common medication used for type 2 diabetes. In addition, it is sometimes prescribed to people with prediabetes or to women with polycystic ovary syndrome (PCOS).
Author Interviews, COVID -19 Coronavirus, Critical Care - Intensive Care - ICUs, Pulmonary Disease / 15.01.2021

MedicalResearch.com Interview with: [caption id="attachment_56422" align="alignleft" width="200"]Dr Andrew Conway Morris Wellcome Trust Clinical Research Career Development Fellow University of Cambridge Hon Consultant in Intensive Care Medicine Addenbrookes Hospital, Cambridge Dr. Conway Morris[/caption] Dr Andrew Conway Morris Wellcome Trust Clinical Research Career Development Fellow University of Cambridge Hon Consultant in Intensive Care Medicine Addenbrookes Hospital, Cambridge MedicalResearch.com: What is the background for this study? Response: Patients with COVID-19 frequently need to come to the intensive care unit (ICU), where we use mechanical ventilation to support their lungs as they get over the intense inflammation caused by the virus.  During the first wave of the virus we noted that a lot of our patients appeared to be developing secondary infections (infections they didn’t have when they came into the ICU). We therefore rolled out a rapid diagnostic test for these secondary bacterial infections that we had developed previously, and this study reports the use of this diagnostic and also describes the types of bacteria seen.  To see if the increase in secondary infections was due to COVID specifically, we compared them to patients who were managed in the same ICU but who did not have COVID.
Author Interviews, COVID -19 Coronavirus, Mental Health Research, Race/Ethnic Diversity, Social Issues, UCSF / 15.01.2021

MedicalResearch.com Interview with: [caption id="attachment_56414" align="alignleft" width="183"]Jason Nagata, MD, MSc Assistant Professor of Pediatrics University of California, San Francisco San Francisco, California Dr. Nagata[/caption] Jason Nagata, MD, MSc Assistant Professor of Pediatrics University of California, San Francisco San Francisco, California MedicalResearch.com: What is the background for this study? Response: Food insecurity is the inability to afford or access nutritionally adequate and safe foods for an active, healthy lifestyle. Rates of food insecurity were projected to rise during the COVID-19 pandemic; however, prior studies had not examined the association between food insufficiency, the most extreme form of food insecurity, and mental health. MedicalResearch.com: What are the main findings? Response: Using a large national sample of nearly 64,000 adults, we found that food insufficiency rose from 8.1% to 10.0% during the pandemic. People of color and younger adults had higher risk of food insufficiency. People living in poverty or experiencing recent job loss were at higher risk of food insufficiency. Food insufficiency was associated with symptoms of anxiety, worrying, and depression. Hunger, exhaustion, and worrying about not getting enough food to eat may worsen depression and anxiety symptoms. Receiving food assistance alleviated the relationship between food insufficiency and poor mental health.  
Author Interviews, COVID -19 Coronavirus, Pulmonary Disease / 12.01.2021

MedicalResearch.com Interview with: [caption id="attachment_56399" align="alignleft" width="200"]MedicalResearch.com Interview with: Dr. Townsend Department of Infectious Diseases St. James's Hospital and Department of Clinical Medicine Trinity Translational Medicine Institute Trinity College, Dublin, Ireland MedicalResearch.com: What is the background for this study? Response: Much is known about the clinical characteristics and pathological features of acute SARS-CoV-2 infection, but there is relatively little known about post-COVID recovery. This has come under increasing scrutiny in light of reports that patients suffer persistent symptoms beyond resolution of initial infection, known as long COVID. We set out to assess patients in our post-COVID clinic for ongoing ill-health, with particular focus on fatigue and breathlessness. Given that COVID-19 primarily affects the respiratory system, we also evaluated respiratory recovery. Patients underwent chest radiography and six-minute-walk testing, as well as routine blood tests including inflammatory markers and D-dimers. We included both patients who were admitted during their acute infection as well as those managed in the community in order to capture the full spectrum of disease. MedicalResearch.com: What are the main findings? Are there any markers that suggest a higher risk of persistent post-Covid symptoms? Response: We assessed 153 patients, of whom 74 had required admission during initial infection, at a median of 75 days post-infection. We found persistent ill-health was common in those attending our clinic, with 62% reporting that they did not feel back to full health. Almost half (47%) met the case definition for fatigue, as assessed by the Chalder Fatigue Scale. Patients also reported moderate breathlessness on six-minute-walk-test, with a median modified Borg score of 3. Reassuringly, we saw persistent abnormal chest x-rays in only 4% of patients, and the median distance covered during walk test was 460m, which approaches the normal range for healthy populations. Furthermore, there were only two patients that experienced oxygen desaturation to less than 90% during walk test. We investigated the potential predictors and associations of breathless, distance covered and abnormal chest x-ray using a multivariate regression analysis model. Interestingly, we found that severity of initial infection, as defined by requirement for admission to hospital, peak CRP and peak oxygen requirement, was not associated with severity of self-reported symptoms. Thus, there were no features from initial infection identified that could predict persistence of symptoms beyond initial infection. MedicalResearch.com: What should readers take away from your report? Response: This study highlights several important points: 1. Ill-health, fatigue and breathlessness are common in the aftermath of SARS-CoV-2 infection 2. These appear unrelated to initial severity of infection. This has implications for the potential number of patients who may be affected, as well as increased burden on the healthcare system 3. We show reassuringly low rates of abnormal chest x-rays as well as reassuring objective six-minute-walk test results, suggesting that clinically significant pulmonary damage is uncommon. MedicalResearch.com: What recommendations do you have for future research as a result of this work? Response: We would suggest that future studies on the aftermath of COVID-19 include patients across the spectrum of disease severity, rather than focusing only on those who required hospitalization. The range and frequency of post-COVID symptoms are being emerging in the literature, and there is a need for mechanistic studies to understand the underlying pathology. We have no disclosures to declare. Citation: Liam Townsend, Joanne Dowds, Kate O'Brien, Grainne Sheill, Adam H Dyer, Brendan O'Kelly, John P. Hynes, Aoife Mooney, Jean Dunne, Cliona Ni Cheallaigh, Cliona O'Farrelly, Nollaig M Bourke, Niall Conlon, Ignacio Martin-Loeches, Colm Bergin, Parthiban Nadarajan, Ciaran Bannan. Persistent Poor Health Post-COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity. Annals of the American Thoracic Society, 2021; DOI: 10.1513/AnnalsATS.202009-1175OC MedicalResearch.com is not a forum for the exchange of personal medical information, advice or the promotion of self-destructive behavior (e.g., eating disorders, suicide). While you may freely discuss your troubles, you should not look to the Website for information or advice on such topics. Instead, we recommend that you talk in person with a trusted medical professional. The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website. Dr. Townsend[/caption] Dr. Liam Townsend, PhD Department of Infectious Diseases St. James's Hospital and Department of Clinical Medicine Trinity Translational Medicine Institute Trinity College, Dublin, Ireland  MedicalResearch.com: What is the background for this study? Response: Much is known about the clinical characteristics and pathological features of acute SARS-CoV-2 infection, but there is relatively little known about post-COVID recovery. This has come under increasing scrutiny in light of reports that patients suffer persistent symptoms beyond resolution of initial infection, known as long COVID. We set out to assess patients in our post-COVID clinic for ongoing ill-health, with particular focus on fatigue and breathlessness. Given that COVID-19 primarily affects the respiratory system, we also evaluated respiratory recovery. Patients underwent chest radiography and six-minute-walk testing, as well as routine blood tests including inflammatory markers and D-dimers. We included both patients who were admitted during their acute infection as well as those managed in the community in order to capture the full spectrum of disease.
Aging, Author Interviews, COVID -19 Coronavirus, Pulmonary Disease / 12.01.2021

MedicalResearch.com Interview with: [caption id="attachment_56395" align="alignleft" width="165"]Dr-Maria A. Blasco Dr. Blasco[/caption] Dr. Maria A. Blasco, PhD Director of the Spanish National Cancer Research Centre Head of the Telomeres and Telomerase Group – CNIO  MedicalResearch.com: What is the background for this study? Response: In my group we have previously described that telomere dysfunction in alveolar type II (ATII) cells in the lung is sufficient to induce pulmonary fibrosis in mice, thus demonstrating that these cells, which have a role in lung regeneration, are at the origin of the disease (Povedano et al., Cell Reports, 2015). Indeed, we further demonstrated that telomere elongation in these cells by using a gene therapy strategy based on telomerase activation, was sufficient to stop the progression of pulmonary fibrosis induced by short telomeres in mice (Povedano, eLife, 2018).
Author Interviews, Brigham & Women's - Harvard, COVID -19 Coronavirus, Heart Disease, JACC / 11.01.2021

MedicalResearch.com Interview with: [caption id="attachment_56374" align="alignleft" width="200"]Rishi K. Wadhera, MD, MPP, MPhil Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center Associate Program Director, Cardiovascular Medicine Fellowship Assistant Professor of Medicine, Harvard Medical School  Dr. Wadhera[/caption] Rishi K. Wadhera, MD, MPP, MPhil Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center Associate Program Director, Cardiovascular Medicine Fellowship Assistant Professor of Medicine, Harvard Medical School  MedicalResearch.com: What is the background for this study? Response: The direct toll of the novel coronavirus disease 2019 (COVID-19) in the U.S. has been substantial, but concerns have also arisen about the indirect effects of the pandemic on higher-risk patients with chronic medical conditions, such as cardiovascular disease. Hospitalizations for acute cardiovascular conditions, including myocardial infarction, heart failure, and stroke precipitously declined during the early phase of the pandemic. These patterns have raised concern that patients may be avoiding hospitals due to fear of contracting SARS-CoV-2, and that some have died from cardiovascular conditions without seeking medical care. In addition, there has been growing concern about the the effects of health-care system strain and the deferral of semi-elective procedures on patients with cardiovascular conditions.
Author Interviews, CDC, COVID -19 Coronavirus, JAMA / 08.01.2021

MedicalResearch.com Interview with: [caption id="attachment_56368" align="alignleft" width="100"]Jay C. Butler, MD, FAAP, MACP, FIDSA Deputy Director for Infectious Diseases Centers for Disease Control and Prevention Atlanta, GA  30333 Dr. Butler[/caption] Jay C. Butler, MD, FAAP, MACP, FIDSA Deputy Director for Infectious Diseases Centers for Disease Control and Prevention Atlanta, GA  30333 MedicalResearch.com: What is the background for this study? Response: There are still disagreements about the significance of transmission of SARS-CoV-2 from asymptomatic persons.  It has been known since at least March 2020 that, unlike the closely related coronavirus that causes SARS, transmission of COVID-19 from asymptomatic and presymptomatic persons occurs and that at least 30% of infected persons do not develop symptoms.  Estimating the proportion of transmissions from persons without symptoms informs the decision analysis for prioritization of community mitigations opportunities:  wearing of masks, social distancing, and hand hygiene. If only a low proportion of transmission occurs from people without symptoms, these interventions would be less likely to control transmission when broadly applied in the community.  On the other hand, if a significant proportion of spread is from infected persons without symptoms, the value of these measures is enhanced. Additionally, obtaining strategic and systematic screening tests for SARS-CoV-2 to identify and isolate persons without symptoms in selected settings, such as congregational housing settings, will have greater potential impact if spread from persons without symptoms is common. 
Author Interviews, COVID -19 Coronavirus, JAMA, Race/Ethnic Diversity, Social Issues, Technology, University of Pennsylvania / 30.12.2020

MedicalResearch.com Interview with: Srinath Adusumalli, MD, MSc, FACC Assistant Professor of Clinical Medicine Division of Cardiovascular Medicine| Penn Medicine Lauren A. Eberly, MD, MPH Division of Cardiovascular Medicine, Department of Medicine Hospital of the University of Pennsylvania, Philadelphia MedicalResearch.com: What is the background for this study?   Response: The coronavirus disease 2019 (COVID-19) pandemic has uprooted conventional health care delivery for routine ambulatory care, requiring health systems to rapidly adopt telemedicine capabilities. At Penn Medicine, we wanted to ensure that as we developed a new system of telemedical care, we were reaching all of the patients we serve and access to care was maintained. As such, we undertook this study to examine utilization of care as we continued to iterate on and develop our telemedical system of care.
Author Interviews, COVID -19 Coronavirus / 30.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56337" align="alignleft" width="200"]Anita M. McGahan PhD, MBA University Professor Professor of Strategic Management Professor, Munk School of Global Affairs & Public Policy George E. Connell Chair in Organizations & Society Rotman School of Management University of Toronto Dr. McGahan[/caption] Anita M. McGahan PhD, MBA University Professor Professor of Strategic Management Professor, Munk School of Global Affairs & Public Policy George E. Connell Chair in Organizations & Society Rotman School of Management University of Toronto MedicalResearch.com: What is the background for this study? What are the main findings? Response:    The article by Phebo Wibbens, Wesley Wu-Yi Koo, and me that came out today in PLOS ONE at https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0244177 investigates how effective different policies are in accomplishing COVID control across 40 different countries and U.S. states.   The policies that we consider are standardized in the Oxford COVID policy database, and include, for example, school closings, workplace closings, international travel controls, restrictions on gatherings, etc.  Each of these policies can be implemented at different levels of intensity.   The analysis looks at the marginal impact of each of these policies in the presence of the others.  We find that, in 90% of jurisdictions, compliance is not high enough to make a core group of socially tolerable policies sufficient to drive COVID growth below zero.   In these places, one or more tougher-to-tolerate policies must be implemented on top of the core group to get COVID growth to stop.
Author Interviews, Clots - Coagulation, COVID -19 Coronavirus, Heart Disease, JAMA / 30.12.2020

MedicalResearch.com Interview with: Ana Blasco, MD, PhD Cardiology Department, Hospital Universitario Puerta de Hierro–Majadahonda Madrid, Spain MedicalResearch.com: What is the background for this study? Response: Our group has been investigating issues related to coronary thrombosis in patients with acute myocardial infarction for years. Recently, we developed a standardized technique for the detection and quantification of extracellular neutrophil networks (NETs) in coronary thrombi. During the first wave of the COVID-19 pandemic in Madrid, Spain, we had some cases of myocardial infarctions with ST elevation and a large thrombotic component among patients with severe SARS-CoV-2 infection. Given the important participation of NETs in severe COVID-19 disease, causing occlusion of microvessels as shown in pulmonary samples, we decided to analyze their role in coronary thrombi. Thanks to similar previous analyzes in patients without COVID-19, we have been able to compare our results with a historical series.
Author Interviews, Brigham & Women's - Harvard, COVID -19 Coronavirus, JAMA, Social Issues / 23.12.2020

MedicalResearch.com Interview with: Kenneth Freedberg, MD Director, Medical Practice Evaluation Center Massachusetts General Hospital Professor of Medicine at Harvard Medical School Study senior author Jessie Gaeta, MD Chief Medical Officer Boston Health Care for the Homeless Program Assistant Professor of Medicine Boston University School of Medicine Travis P. Baggett, MD, MPH Faculty clinician-investigator MGH Division of General Internal Medicine Assistant Professor of Medicine Harvard Medical School MedicalResearch.com: What are the main findings?  Dr. Baggett: We found that two strategies are crucial for addressing COVID-19 among people staying in homeless shelters: 1) Proactively identifying and testing people with symptoms, and 2) Providing a dedicated, medically supervised, non-hospital space for isolation and management of people with mild to moderate COVID. Together these two strategies would reduce infections, hospitalizations, and health care costs compared to not doing them. During a pandemic surge, like we are seeing now, it makes sense to add periodic universal testing of all shelter residents, even those without symptoms.
Annals Internal Medicine, Author Interviews, Brigham & Women's - Harvard, COVID -19 Coronavirus, Education / 23.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56315" align="alignleft" width="200"]Elena Losina, PhD Robert W. Lovett Professor of Orthopedic Surgery Harvard Medical School Director, Policy and Innovation eValuations in Orthopedic Treatments (PIVOT) Center Co-Director, Orthopedic and Arthritis Center for Outcomes Research Department of Orthopedic Surgery Brigham and Women’s HospitalBoston, MA, 02115 Dr. Losina[/caption] Elena Losina, PhD Robert W. Lovett Professor of Orthopedic Surgery Harvard Medical School Director, Policy and Innovation eValuations in Orthopedic Treatments (PIVOT) Center Co-Director, Orthopedic and Arthritis Center for Outcomes Research Department of Orthopedic Surgery Brigham and Women’s HospitalBoston, MA, 02115 MedicalResearch.com: What is the background for this study? Response: Since the pandemic began, there have been over 320,000 COVID-19 cases and 80 deaths at over 1,700 colleges, highlighting the consequences of different mitigation strategies, and as colleges are closing the fall semester and preparing for the spring semester, figuring out what worked what did not, in term of COVID-19 mitigation, is critical to minimize the impact of COVID-19 on college campuses during the spring semeste. 
Abuse and Neglect, Author Interviews, COVID -19 Coronavirus, Emergency Care, Heart Disease / 21.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56306" align="alignleft" width="171"]Michalis Katsoulis PhD Immediate PostDoctoral BHF fellow Institute of Health Informatics Senior Research Fellow, UCL Dr. Katsoulis[/caption] Michalis Katsoulis PhD Immediate PostDoctoral BHF fellow Institute of Health Informatics Senior Research Fellow, UCL MedicalResearch.com: What is the background for this study? Response: In the early stage of the pandemic, we observed a decline in patient visits to Emergency Departments (ED), including those for cardiac diseases. This decline may have been due to fear of coronavirus infection when attending hospital, public reluctance to overload National Health Service facilities, or difficulty accessing care. In our study, we tried to estimate the impact of reduced ED visits on cardiac mortality in England. We used data from ED visits from the Public Health England Emergency Department Syndromic Surveillance System (EDSSS). For cardiovascular disease outcomes, we obtained mortality counts for cardiac disease from the Office of National Statistics (ONS) for England.
Author Interviews, COVID -19 Coronavirus, Genetic Research, NYU/NYMC / 19.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56272" align="alignleft" width="200"]John T. Poirier, PhD Assistant Professor of Medicine, NYU Grossman School of Medicine Director, Preclinical Therapeutics Program Perlmutter Cancer Center An NCI-designated Comprehensive Cancer Center NYU Langone Health Smilow Research Center New York, NY 10016  Dr. Poirier[/caption] John T. Poirier, PhD Assistant Professor of Medicine, NYU Grossman School of Medicine Director, Preclinical Therapeutics Program Perlmutter Cancer Center An NCI-designated Comprehensive Cancer Center NYU Langone Health Smilow Research Center New York, NY 10016  MedicalResearch.com: What is the background for this study? Response: The goal of this study was to identify in as much detail as possible the genes that SARS-CoV-2, the virus that causes COVID-19, needs to successfully infect a human host cell. CRISPR technology played a key role in this research; it was used to disrupt every gene in the human genome in parallel and study which ones were required for infection.
Author Interviews, COVID -19 Coronavirus, JAMA, University of Pennsylvania, Vaccine Studies / 18.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56241" align="alignleft" width="180"]Emily Largent, PhD, JD, RN Senior Fellow Leonard Davis Institute of Health Economics Assistant Professor, Medical Ethics and Health Policy  Perelman School of Medicine Dr. Largent[/caption] Emily Largent, PhD, JD, RN Senior Fellow Leonard Davis Institute of Health Economics Assistant Professor, Medical Ethics and Health Policy Perelman School of Medicine  MedicalResearch.com: What is the background for this study? Response: Ending the COVID-19 pandemic through vaccination will require sufficient vaccine uptake.  Various means are being considered to promote uptake, including mandatory vaccination.  For instance, COVID-19 vaccination might be mandated by states (e.g., as a condition for children to attend public school) or by employers.  Given the opposition we’ve seen to masks, to choose just one example, our team wanted to gauge the acceptability of COVID-19 vaccine mandates.
Author Interviews, Cancer Research, COVID -19 Coronavirus, Lung Cancer / 17.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56247" align="alignleft" width="155"]Robert Van Haren, MD, MSPH College of Medicine University of Cincinnati Dr. Van Haren[/caption] Robert Van Haren, MD, MSPH College of Medicine University of Cincinnati  MedicalResearch.com: What is the background for this study? Response: The COVID-19 pandemic has impacted all areas of society including the field of oncology. This study evaluated the impact of COVID-19 on lung cancer screening.  Screening with low-dose computed tomography (LDCT) scans are important because they reduce lung cancer mortality by at least 20%.  Our lung cancer screening program was closed in March 2020 due to COVID 19 and reopened again in June 2020.  We cancelled over 800 LDCTs during that time period. 
Author Interviews, COVID -19 Coronavirus / 17.12.2020

MedicalResearch.com Interview with: Xiaolei Yang  The State Key Laboratory of Nonlinear Mechanics, Institute of Mechanics School of Engineering Sciences University of Chinese Academy of Sciences Beijing, China hallway-air-flow.jpegMedicalResearch.com: What is the background for this study? What are the main findings? Response: The most important finding of this study is that the transmission of COVID-19 is highly influenced by the airflow and that a slight difference in the airflow can significantly alter the virus spreading pattern in the air. In this study, the change of airflow is caused by a minor difference in the corridor width and the walking speed. However, such a change can also come from other factors, such as the indoor architectural structure, the temperature, the humidity, etc. In many of these cases, the common guideline of 6-feet may not be enough when the influence of airflow is taken into account. Due to this complexity, there is still a gap of knowledge to fill before a safety guideline for different indoor environments can be provided to the public, many research efforts are needed from the fluid mechanics’ aspect.
Author Interviews, Brigham & Women's - Harvard, COVID -19 Coronavirus, Critical Care - Intensive Care - ICUs, End of Life Care / 14.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56226" align="alignleft" width="200"]Isaac Chua, MD, MPH Division of General Internal Medicine and Primary Care Brigham and Women's Hospital Dr. Chua[/caption] Isaac Chua, MD, MPH Division of General Internal Medicine and Primary Care Brigham and Women's Hospital MedicalResearch.com: What is the background for this study? Response: Patient surveys have shown that most people prefer to die at home at the end-of-life. However, during the initial wave of the COVID-19 pandemic, anecdotal evidence from our colleagues and findings from a prior study published in the Journal of the American Geriatrics Society suggested that majority of COVID-19 decedents died in a medical facility. However, less is known about care intensity at the end-of-life according to place of death among patients who died of COVID-19. Therefore, we characterized end-of-life care by place of death among COVID-19 decedents at Mass General Brigham (MGB), the largest health system in Massachusetts. 
Author Interviews, COVID -19 Coronavirus, OBGYNE / 13.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56223" align="alignleft" width="177"] Dr. Maru[/caption] Sheela Maru, MD, MPH Department of Health System Design and Global Health and Arnhold Institute for Global Health and Department of Obstetrics, Gynecology and Reproductive Science Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Response: Universal screening for SARS-CoV-2 infection on Labor and Delivery (L&D) units is a critical strategy to manage patient and health worker safety, especially in a vulnerable high-prevalence community. We describe the results of a SARS-CoV-2 universal screening program at the L&D Unit at Elmhurst Hospital in Queens, NY, a 545-bed public hospital serving a diverse, largely immigrant and low-income patient population and an epicenter of the global pandemic.
Author Interviews, COVID -19 Coronavirus, CT Scanning, Johns Hopkins, Nature / 12.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56220" align="alignleft" width="120"]Nilanjan Chatterjee, PhD Bloomberg Distinguished Professor Departments of Biostatistics and Epidemiology Johns Hopkins Bloomberg School of Public Health Dr. Chatterjee[/caption] Nilanjan Chatterjee, PhD Bloomberg Distinguished Professor Departments of Biostatistics and Epidemiology Johns Hopkins Bloomberg School of Public Health  MedicalResearch.com: What is the background for this study? Response: Calculation of risks or severe COVID-19 disease and mortality for individuals in the general population can help to prioritize prevention efforts, such as early vaccination. We developed a model to estimate risks for COVID-19 mortality for currently uninflected individuals based on sociodemographic factors, pre-existing conditions and local pandemic intensity.  The model captures factors associated with both risk of infection and complications after infection. The model was developed using information from a large UK based cohort study called OpenSAFELY, and was adapted to the US population based on information on mortality rate associated with age and race/ethnicity available through CDC.  The model also utilizes information on state level projected death rates from pandemic forecasting models. 
Author Interviews, COVID -19 Coronavirus, Environmental Risks, Science / 11.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56202" align="alignleft" width="133"]Asimanshu Das, Ph.D. student Brown University School of Engineering Asimanshu Das[/caption] Asimanshu Das, Ph.D. student Brown University School of Engineering MedicalResearch.com: What is the background for this study? What are the main findings? Response: Driving in a car with  ride-share or car-pool is a widely prevalent social interaction. The study aimed to address the airflows inside cars in various window open/closed configurations using computer simulations, and also looking into the possibility of movement of aerosol-type of particles from one occupant to other. The main findings are that opening windows provides a likely benefit to reduce the potentially pathogenic aerosols inside the cabin. Generally, more windows the better, but at the least it would be advisable to have one rear side window and one frontside window open.
Author Interviews, Breast Cancer, Cancer Research, COVID -19 Coronavirus / 10.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56183" align="alignleft" width="200"]Joanne L. Blum, MD, PhD, FACP Texas Oncology and Director Hereditary Cancer Risk Program Baylor University Medical Center Dr. Blum[/caption] Joanne L. Blum, MD, PhD, FACP Texas Oncology and Director Hereditary Cancer Risk Program Baylor University Medical Center MedicalResearch.com: What is the background for this study? Would you briefly describe the POLARIS study? Response: POLARIS is an ongoing prospective, real-world, non-interventional study in patients with HR+/HER2-ABC receiving palboiclib plus endocrine therapy with a targeted enrollment of 1500 patients at 110 sites in the United States and Canada.  MedicalResearch.com: What are the main findings?
  • Because of the COVID-19 pandemic, approximately one third of the study sites experienced an impact on their responsiveness to correspondence, timely data entry, and subject management.
  • The geographic location or type (e.g., academic or community) of study site appears associated with whether the site was impacted by COVID-19.
  • Other study site characteristics were generally similar between sites that reported an impact of COVID-19 and those that were not impacted.
  • Because of inherent limitations of survey studies, these findings must be interpreted with caution.
Author Interviews, Infections / 09.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56179" align="alignleft" width="200"]Ed Breitschwerdt, DVM, DACVIM The Melanie S. Steele Distinguished Professorship in Medicine Professor Internal Medicine NC State College of Veterinary Medicine Dr. Breitschwerdt[/caption] Ed Breitschwerdt, DVM, DACVIM The Melanie S. Steele Distinguished Professorship in Medicine Professor, Internal Medicine NC State College of Veterinary Medicine MedicalResearch.com: What is the background for this study? Response: Bartonella species represent a medically underappreciated group of vector-transmitted bacteria that are increasingly implicated in a spectrum of animal and human diseases. Most recently, our research group has focused on the potential role of these bacteria as a cause or co-factor in patients with neuropsychiatric symptoms. This focus is based upon prior case reports and case series generated by our research group and others.
Alcohol, Author Interviews, COVID -19 Coronavirus / 07.12.2020

MedicalResearch.com Interview with: [caption id="attachment_56164" align="alignleft" width="200"]Sitara Weerakoon, MPH (she/her) PhD Candidate | Epidemiology & Biostatistics Graduate Research Assistant Center for Pediatric Population Health UTHealth  Sitara Weerakoon[/caption] Sitara Weerakoon, MPH (she/her) PhD Candidate | Epidemiology & Biostatistics Graduate Research Assistant Center for Pediatric Population Health UTHealth MedicalResearch.com: What is the background for this study? What are the main findings? Response: Measures to control the spread of COVID-19 included stay-at-home mandates and business lockdown policies which resulted in many facing a loss of income or employment and more time spent isolated at home. Life stressors (like job loss and social isolation) have been shown to be associated with increased drinking at unhealthy levels. Those with a history of mental health problems may be even more at risk. We aimed to see if binge drinking (5 or more drinks [male] or 4 or more drinks [female] in one session) and levels of alcohol consumption among binge drinkers were impacted by these pandemic-related factors. We found that increased time spent at home (in weeks) was associated with a 19% increase in the odds of binge drinking and binge drinkers with a previous diagnosis of depression and current depression symptoms (during the early months of the pandemic) had a 237% greater odds of drinking more alcohol (vs drinking the same amount) compared to those with no history and current symptoms of depression.
Author Interviews, COVID -19 Coronavirus / 07.12.2020

MedicalResearch.com Interview with: Prof. Martin Scholz Heinrich-Heine-University Düsseldorf, Germany MedicalResearch.com: What is the background for this study? Response: Primary care physicians should have options available to effectively treat newly diagnosed COVID-19 patients in the outpatient setting to avoid severe COVID-19 progression, hospitalizations, and mortality. Already since the beginning of the pandemic different early treatment options were evaluated. My co-authors, Dr. Zelenko, Dr. Derwand, and myself were keen to confirm retrospectively the observed evidence for beneficial early treatment effects of an already applied  triple therapy in combination with a risk stratification approach. The defined risk stratification allowed to differentiate between patients at low and high risk for disease progression and guided treatment decisions.